Point72 Asia (Singapore) Pte. Ltd. Travere Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $532 Billion
- Q3 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 4,037 shares of TVTX stock, worth $71,535. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,037
Previous 35,377
88.59%
Holding current value
$71,535
Previous $291 Million
80.58%
% of portfolio
0.01%
Previous 0.06%
Shares
2 transactions
Others Institutions Holding TVTX
# of Institutions
192Shares Held
84.5MCall Options Held
776KPut Options Held
900K-
Armistice Capital, LLC New York, NY7.65MShares$136 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$135 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$122 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$83 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$76.9 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.14B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...